Dandrit strengthens its European Patent base. This company has potential of surpassing rival Dendreon in the field of Cancer Vaccine  Astonishing – but true….

Dandrit A/s is through merger of cash-rich DKTI A/S securing a financial platform for expansion and a platform on the Copenhagen Stock Exchange.  Ongoing talks – that were first publicized late 2011 have now resulted in a proposed merger – please see details here.

DanDrit Biotech A/S is a clinical-stage company  developing the world’s first vaccine against colorectal cancer. DanDrit technology is based on development of dendritic cell vaccines. Like Dendreon – DanDrit’ base their development on a single lead compound,  (in Dandrit’s case called) MelCancerVac, an allogenic dendritic cell vaccine.  Dandrit has completed two Phase II clinical trials for the treatment of advanced colorectal cancer and non-small cell lung cancer (NSCLC). DanDrit now takes MCV into a randomized comparative Phase IIb / III clinical trial in advanced colorectal cancer.

Presently the vaccine can be used for compassionate use (Singapore)


Dandrit is enhancing ist patent base.



About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂

Tagged with:

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.